Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Jan;53(1):35-43.
doi: 10.1016/j.dld.2020.10.018. Epub 2020 Nov 5.

Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus

Aurélien Amiot  1 , Guillaume Bouguen  2 , Guillaume Bonnaud  3 , Yoram Bouhnik  4 , Hervé Hagege  5 , Laurent Peyrin-Biroulet  6 ; French National Consensus Clinical guidelines for the management of IBD study group
Collaborators, Affiliations
Free article
Practice Guideline

Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus

Aurélien Amiot et al. Dig Liver Dis. 2021 Jan.
Free article

Abstract

Background: New treatments and therapeutic approaches repeatedly emerged in the field of inflammatory bowel disease.

Aim: to update the French treatment algorithms for Crohn's disease (CD) and ulcerative colitis (UC).

Methods: A formal consensus method was used to determine changes to the treatment algorithms for various situations of CD and UC. Thirty-seven experts voted on questions that had been drafted by the steering committee ahead of time. Consensus was defined as at least 66% of experts agreeing on a response.

Results: Anti-TNF were reinforced as a first-line therapy rather than the use of immunosuppressant alone. Vedolizumab for UC, ustekinumab for CD took place as second-line maintenance therapy and potentially as a first-line therapy in the setting of unrestricted reimbursement for vedolizumab. Tofacitinib was recommended by the experts in case of vedolizumab failure for UC. Algorithms for complicated CD with abscess, intestinal and complex anal fistula were updated according to recent prospective cohort studies.

Conclusion: The changes incorporated to the algorithms provide up-to-date and easy-to-use guidelines to treat patients with IBD.

Keywords: Algorithm; Clinical guidelines; Consensus; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Aurelien Amiot received consulting fees from Abbvie, Hospira, Takeda, Gilead and Biocodex as well as lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Takeda and MSD. This author also received advisory board fees from Gilead, Takeda and Abbvie Guillaume Bouguen received lecture fees from Abbvie, Ferring, MSD, Takeda and Pfizer and consultant fees from Takeda, Janssen. Guillaume Bonnaud received consulting fees from AbbVie, Alfa Sigma, AMGEN, Bouchara-recordati, Ferring, IPSEN, Janssen, Medtronic, MSD, Mylan, Norgine, Pfizer, Takeda, TILLOTS, Vifor Yoram Bouhnik received lecture and consulting fees from Abbvie, Biogaran, Boehringer-Ingelheim, CTMA, Ferring, Gilead, Hospira, ICON, Inception IBD, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Robarts Clinical Trials, Roche, Sanofi, Shire, Takeda, UCB and Vifor Pharma. This author has also stock ownership of Inception IBD, San Diego, CA, USA. Herve Hagège received consulting fees from Abbvie, Alfasigma, Ferring, Janssen, Norgine, Mayoly Spindler, MSD, Takeda, Tillotts. Laurent Peyrin-Biroulet has received consulting fees from Merck, Abbvie, Janssen, Genentech, Ferring, Norgine, Tillots, Vifor, Shire, Therakos, Pharmacosmos, Pilège, BMS, UCB-Pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, and HAC-Pharma. This author has also received lecture fees from Merck, Abbvie, Takeda, Janssen Cilag, Ferring, Norgine, Tillots, Vifor, Therakos, HAC-Pharma, and Mitsubishi.

Publication types

MeSH terms

Substances